Triplet cytotoxic chemotherapy with @entity136 , @entity1487 and @entity900 for advanced XXXX .

@entity1 @entity788 @entity66 @entity882 @entity900 @entity420 @entity1398 @entity1431 @entity1349 @entity136 @entity1487
UNASSIGNED: In advanced or relapsed @entity788 , mono- or duo-therapy has shown modest efficacy at best. The present study evaluated the efficacy of a triplet combination in relapsed or advanced @entity788 . A total of 37 @entity1 with @entity420 in stage III/IV or with @entity66 were treated with a @entity136 , @entity1487 and @entity900 (GFP) regimen every 3 weeks. Only 29 out of 37 @entity1 were evaluable for response due to early treatment interruption in 8 @entity1 . The overall response rate was 24.1% and the disease control rate was 68.9%. The progression-free survival (PFS) rate was 61.5, 30.9 and 17.6% at 3, 6 and 9 months, respectively, and the @entity1349 ( @entity1349 ) rate was 46.5 and 30.6% at 6 and 12 months, respectively. Grade 3/4 @entity1431 , @entity1398 and @entity882 occurred in 18.4, 29.9 and 24.5% of 147 cycles, respectively. Old age and a poor performance status (PS) were associated with the early discontinuation of chemotherapy (P=0.038 and P=0.036, respectively). In @entity1 <65 years old and with a PS of <2, the median PFS and @entity1349 times were 5.3 months and 10.3 months, respectively. Overall, although GFP resulted in acceptable response and survival rates, it does not appear to have marked superiority to @entity136 -based single or duplet chemotherapy.
